
-
Akero Therapeutics NasdaqGS:AKRO Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Location: 601 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://akerotx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.308B
Cash
686.3M
Avg Qtr Burn
-65.66M
Short % of Float
9.54%
Insider Ownership
1.38%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Efruxifermin (FGF-21 mimetic) Details Compensated cirrhosis (F4) due to MASH | Phase 3 Data readout | |
Efruxifermin (FGF-21 mimetic) Details Pre-cirrhotic MASH with fibrosis stages F2–F3, Non-invasively diagnosed MASLD (F1–F4 fibrosis) | Phase 3 Data readout | |
Efruxifermin Details Compensated cirrhosis (F4, Child-Pugh A) due to MASH | Phase 2b Data readout | |
Efruxifermin (FGF-21 mimetic) Details Pre-cirrhotic MASH with fibrosis stages F2–F3 | Phase 2b Update |